)
Visual24 Oct 2025
The rise of Alphabet
Prothena Corporation (PRTA) investor relations material
Prothena Corporation Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Cantor Global Healthcare Conference 2025 summary4 Sep, 2025
Recent corporate developments
Multiple pipeline updates and positive news from partners, including Roche and Novo, with both moving key molecules into phase three studies this year.
Restructuring led to a right-sized organization focused on ongoing partner obligations and new partnership opportunities.
Shareholder-friendly financial activities, including plans for distributable reserves and potential share repurchase, are underway.
Operational clarity and focus on near-term value creation, with $105M in clinical milestones achievable next year.
End-of-year cash guidance is $300M, with further 2026 guidance to be provided early next year.
Pipeline and partnership updates
Roche is advancing prasinezumab for Parkinson’s disease into phase three, with additional data expected and a large market opportunity projected.
Novo Nordisk is moving Kuramitug for ATTR cardiomyopathy into phase three, with a significant milestone payment expected upon enrollment.
Four active partnership programs: two entering phase three, one phase two readout in 2027, and one phase one with Bristol Myers Squibb.
Ongoing efforts to partner unpartnered programs and fulfill R&D obligations for current collaborations.
Partnership economics include up to $755M in milestones and royalties with Roche, and $1.23B in milestones and royalties with Novo Nordisk.
Clinical and scientific highlights
PRX012, an anti-amyloid beta antibody for Alzheimer’s, showed strong potency and favorable PK but higher than expected ARIA rates; a transferrin-based approach is being considered to mitigate this.
Prasinezumab targets aggregated alpha synuclein in Parkinson’s, with consistent effects across studies and a unique biological profile.
Kuramitug targets misfolded transthyretin in ATTR amyloidosis, aiming to clear resident amyloid and prevent new aggregation, with encouraging early clinical data.
Phase two and three studies are designed to address both symptomatic and disease-modifying aspects in neurodegenerative diseases.
Future milestones include clinical data readouts, regulatory decisions, and potential commercial launches.
PRXO12: How to mitigate ARIA and partner?
Explain Prasinezumab's L-DOPA subgroup effect.
Evidence for Karamatug's plaque clearance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Prothena Corporation earnings date
Q3 202511 Nov, 2025
Next Prothena Corporation earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies for diseases caused by protein dysregulation. The company's portfolio includes a range of investigational humanized antibodies and other therapeutic candidates targeting conditions such as AL amyloidosis, Parkinson's disease, ATTR amyloidosis, and Alzheimer's disease. Prothena's approach leverages insights into the biology of misfolded proteins to develop therapies aimed at changing the course of neurodegenerative and rare peripheral amyloid diseases. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage